Lexology January 17, 2025
Sidley Austin LLP

In December 2024, the U.S. Food and Drug Administration (FDA) released its finalized guidance on the Advanced Manufacturing Technologies (AMT) Designation Program, marking a significant milestone in the agency’s efforts to modernize pharmaceutical manufacturing. This program is designed to facilitate the adoption of innovative manufacturing technologies that can enhance drug quality, ensure a robust supply chain, and expedite the development and availability of critical medications.

This guidance finalizes the draft guidance of the same title issued on December 13, 2023. FDA considered comments received on the draft guidance and in response made changes to the final guidance including clarifying the following:

  • the process of submitting a request for AMT designation to FDA
  • description of eligibility criteria to receive AMT...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
On Heels of FDA Nod, BridgeBio’s Rival to Blockbuster Pfizer Drug Wins European Approval
STAT+: Pharmalittle: We’re reading about RFK Jr. targeting CDC and FDA advisers, a Pfizer gene therapy, and more
AI-powered MRI cancer-screening tool receives FDA clearance
Device industry scrambles as FDA job cuts cause delays
FDA approves first rapid-acting insulin biosimilar for diabetes

Share This Article